Abstract:Background: Penile squamous cell carcinoma (PSCC) is a human papillomavirus (HPV)-associated malignancy. Immunotherapy is emerging as a potential treatment for advanced PSCC. In this study, the authors analyzed the association of HPV status with outcomes and the immune microenvironment in patients with advanced PSCC undergoing programmed cell death protein 1 (PD1) inhibitor-based combination therapy (PCT). Methods: HPV status was assessed using quantitative polymerase chain reaction in 87 patients with advanced PSCC treated with PCT. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in the HPV+ and HPV- groups were compared. Additionally, bulk RNA sequencing was performed to investigate the potential impact of HPV on the immune microenvironment in advanced PSCC. Results: Among patients receiving first-line PCT, ORR (91.7% vs. 64.6%, p = .014) and DCR (100.0% vs. 79.2%, p = .025) in the HPV+ group were higher compared to the HPV- group. Kaplan-Meier curves demonstrated that the HPV+ group exhibited superior PFS (p = .005) and OS (p = .004) for patients in the first-line setting. However, these advantages of HPV infection were not observed in multi-line PCT (p > .050). HPV status remained an independent prognostic factor for predicting better ORR (p = .024), PFS (p = .002), and OS (p = .020) in the multivariate analyses. Landmark analyses showed that the HPV-induced superiority of PFS occurred at an early stage (within 3 months) and OS occurred at a relatively late stage (within 9 months). Bioinformatic analyses identified potential immune-activated genes (GLDC, CYP4F12, etc.) and pathways (RAGE, PI3K/AKT, etc.), antitumor immune cell subtypes, and lower tumor immune dysfunction and exclusion scores in HPV+ tissues. Conclusions: HPV infection may confer treatment efficacy and survival benefits in patients with advanced PSCC receiving first-line PCT because of the possible stimulation of the antitumor immune microenvironment. Plain language summary: Human papillomavirus (HPV) infection may induce better objective response rate, progression-free survival (PFS), and overall survival (OS) for advanced penile squamous cell carcinoma (PSCC) patients receiving first-line programmed cell death protein 1 inhibitor-based combination therapy (PCT) instead of multi-line PCT. HPV infection-induced PFS advantage occurs at an early stage (within 3 months) whereas OS superiority occurs at a relatively late stage (within 9 months). Antitumor immune microenvironment could be stimulated by HPV infection in advanced PSCC tissues.

Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance

Endocervical Adenocarcinoma with Micropapillary Component, a Distinct Histological Subtype Associated with Aggressive Behavior and Poor Prognosis: A Clinicopathologic Study of 10 Patients

The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma

Independent Validation of Distinct Clinicopathological Features and Prognosis among Usual-Type, Mucinous-Type and Gastric-Type Endocervical Adenocarcinoma Categorised by New WHO Classification (2020).

PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes

Endocervical adenocarcinomas classified by International Endocervical Adenocarcinoma Criteria and Classification: a clinicopathological and prognostic analysis of 286 cases

PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma

Clinicopathological Features and Outcomes in Different Histologic Subtypes of HPV-independent Endocervical Adenocarcinomas

Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer

Clinicopathological Features and Outcomes in Gastric-Type of HPV-independent Endocervical Adenocarcinomas

International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Expression of PD-1, PD-L1 and PD-L2 is Associated with Differentiation Status and Histological Type of Endometrial Cancer

Prevalence and Prognostic Role of PD-L1 in Patients with Gynecological Cancers: A Systematic Review and Meta-Analysis

PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance

Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer

PD-L1 and PD-1 Expression Correlate with Prognosis in Extrahepatic Cholangiocarcinoma

Expression Patterns of Programmed Death Ligand 1 Correlate with Different Microenvironments and Patient Prognosis in Hepatocellular Carcinoma.

Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy